Lexaria Bioscience Corp (LEXX)
3.07
+0.61
(+24.80%)
USD |
NASDAQ |
Apr 30, 15:01
Lexaria Bioscience Revenue (Quarterly): 0.145M for Feb. 29, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | 0.145M |
| November 30, 2023 | 0.1513M |
| August 31, 2023 | -0.0034M |
| May 31, 2023 | 0.0931M |
| February 28, 2023 | 0.02M |
| November 30, 2022 | 0.0977M |
| August 31, 2022 | 0.1111M |
| May 31, 2022 | 0.0997M |
| February 28, 2022 | 0.0307M |
| November 30, 2021 | 0.0139M |
| August 31, 2021 | 0.031M |
| May 31, 2021 | 0.2041M |
| February 28, 2021 | 0.192M |
| November 30, 2020 | 0.2957M |
| August 31, 2020 | 0.1337M |
| May 31, 2020 | 0.0364M |
| February 29, 2020 | 0.0375M |
| November 30, 2019 | 0.0103M |
| August 31, 2019 | 0.1251M |
| May 31, 2019 | 0.0599M |
| February 28, 2019 | 0.0153M |
| November 30, 2018 | 0.0222M |
| August 31, 2018 | 0.0964M |
| May 31, 2018 | 0.1403M |
| February 28, 2018 | 0.172M |
| Date | Value |
|---|---|
| November 30, 2017 | 0.0246M |
| August 31, 2017 | 0.0126M |
| May 31, 2017 | 0.0293M |
| February 28, 2017 | 0.0126M |
| November 30, 2016 | 0.0092M |
| August 31, 2016 | 0.0086M |
| May 31, 2016 | 0.0062M |
| February 29, 2016 | 0.0152M |
| November 30, 2015 | 0.0108M |
| August 31, 2015 | 0.0046M |
| May 31, 2015 | 0.0072M |
| February 28, 2015 | 0.0029M |
| November 30, 2014 | |
| July 31, 2014 | 0.1359M |
| April 30, 2014 | 0.1678M |
| January 31, 2014 | 0.1601M |
| October 31, 2013 | -0.8564M |
| July 31, 2013 | 0.2515M |
| April 30, 2013 | 0.2534M |
| January 31, 2013 | 0.3515M |
| October 31, 2012 | 0.469M |
| July 31, 2012 | 0.4945M |
| April 30, 2012 | 0.1449M |
| January 31, 2012 | 0.2494M |
| October 31, 2011 | 0.2568M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.0034M
Minimum
Aug 2023
0.2957M
Maximum
Nov 2020
0.0942M
Average
0.0954M
Median
Revenue (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 45.10M |
| Sunshine Biopharma Inc | 7.680M |
| Acasti Pharma Inc | -- |
| Edesa Biotech Inc | -- |
| Xenon Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.6495M |
| Total Expenses (Quarterly) | 0.813M |
| EPS Diluted (Quarterly) | -0.06 |
| Enterprise Value | 26.53M |
| Profit Margin (Quarterly) | -448.0% |
| Earnings Yield | -22.15% |
| Normalized Earnings Yield | -22.00 |